Overview

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2035-02-28
Target enrollment:
Participant gender:
Summary
Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
Phase:
PHASE1
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Regeneron Pharmaceuticals